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Abstract
Nucleotides have effects on immune cells which are complex but generally proinflammatory, and have been suggested to
play a role in smoking-related lung diseases. However, there have been no studies directly measuring functional responses
to nucleotides in human lungs taken from smokers. We used fragments of post mortem human lung from smokers and non-
smokers, incubated them with a range of nucleotides (4–1000 mM) in the presence of lipopolysaccharide (LPS; 10 mg/ml) for
24 hours and measured cytokines (IL-1b, IFNc, IL-17, TNFa, IL-6, IL-8, IL-2 and IL-10) in the supernatants using multiplex
immunoassays. Although the basal cytokine levels in the smokers were generally higher in the smokers than the non-
smokers, there were no significant differences in either the basal release or the LPS-stimulated release of any of the
cytokines when lungs from smokers and non-smokers were compared. There were no significant effects of ATP, ADP, AMP,
UTP, a,b-methylene-ATP, P1, P4-diATP, 2-methylthio-ATP or Bz-ATP on the release of cytokines from the lungs. However, the
stable ATP analogue ATPcS increased the release of IL-1b and IFNc, and the effect was greatly increased in lungs from
smokers. In non-smokers but not in smokers ATPcS increased the release of IL-17. Overall these results clearly demonstrate
for the first time that in normal human lung a stable ATP analogue can enhance LPS-induced pro-inflammatory cytokine
release, and that these effects are greatly altered by a prior history of smoking. This provides strong support for the
suggestion that nucleotides are involved in the pathogenesis of smoking-related diseases.
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Introduction
There is increasing interest in the role of nucleotides in immune
and inflammatory responses, and in particular their role in lung
diseases [1]. There are currently known to be eight subtypes of G
protein coupled P2Y receptors (P2Y1,2,4,6,11,12,13,14) and seven
subtypes of ionotropic P2X receptors (P2X 1–7) which respond to
purine and pyrimidine nucleotides [2], and nearly all of these
subtypes can be found on cells in the airways [1]. It has been
suggested that ATP may play a role in the pathogenesis of asthma,
and allergen challenge has been shown to result in an increase in
ATP in bronchoalveolar lavage fluid from asthmatic patients [3].
In a mouse model of asthma, allergen challenge also resulted in an
increase in ATP concentrations in bronchoalveolar lavage fluid
(BALF) and caused asthma-like symptoms which could be
inhibited by administration of apyrase (which breaks down ATP)
or by non-selective ATP antagonists such as suramin [3]. These
findings were interpreted as indicating recruitment and activation
of lung dendritic cells by ATP, resulting in induction of asthma-
like responses. The P2X7 receptor has been suggested to be
involved in this process, and P2X7 knockout mice display reduced
airway reactivity and leukocyte recruitment [4]. The P2X7
receptor is known to play a key role in the processing and release
of the proinflammatory cytokine IL-1b [5–8], and in patients with
asthma P2X7 receptors are upregulated on eosinophils and on
macrophages in bronchoalveolar lavage fluid, which secreted
larger amounts of IL-1b in response to a P2X7 agonist [4].
Reduced P2X7 function was associated with a lower incidence of
asthma in children at high risk of the disease [9].
Emphysema and chronic obstructive pulmonary disease
(COPD) are smoking-related lung diseases in which ATP has
been suggested to play a role [1,10]. In studies in mice, exposure to
cigarette smoke increased the amount of ATP in BALF, and this
was associated with inflammation and emphysema. Cigarette
smoke caused the release of ATP from neutrophils, an increase in
ATP in BALF and upregulation of P2 receptors on neutrophils,
macrophages and lung tissue [11,12]. Both cigarette smoke and
ATP caused the release of the chemokine CXCL8 and elastase
(both of which are involved in emphysema and COPD) which
could be prevented by suramin or apyrase [11]. Suramin also
reduced the smoke-induced lung inflammation and emphysema,
and genetic deletion of the P2Y2 receptor reduced the smoke-
induced production of cytokines including IFN-c and IL-1b and
was also protective against smoke-induced inflammation [12].
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Genetic deletion of the P2X7 receptor or a selective P2X7
antagonist has also been shown to reduce smoke-induced
macrophage and neutrophil accumulation, release of a variety of
cytokines, including IL-1b and caspase 1 activation, which is a key
step in the release of IL-1b [13,14].
In a human study comparing non-smokers, healthy smokers and
patients with COPD, there was a progressive increase in these
groups in ATP levels in BALF, acute smoke exposure led to a
further increase in the smokers and ATP levels were negatively
correlated with lung function in the COPD patients [15]. Exhaled
breath condensates from patients with COPD contained higher
levels of purines than those from healthy subjects, and the levels
correlated with the severity of the disease [16]. In addition,
enhanced responses to ATP were found in blood neutrophils and
airway macrophages taken from patients with COPD, and there
was upregulation of P2Y2 and P2X7 receptors respectively on
these cells. In particular, there was an increase in ATP-induced IL-
1b release from airway macrophages isolated from BALF taken
from patients with COPD, a response mediated through activation
of P2X7 receptors [15]. Lung tissue from patients with COPD or
from smokers had higher levels of caspase 1 activity than lung
tissue from non-smokers [13], which could have been a result of
increased activation of the P2X7 receptor although this was not
addressed in this study.
The studies discussed above implicate ATP as the mediator of
cigarette-smoke-induced release of inflammatory mediators, and
suggest that ATP plays an important role in the pathogenesis of
smoking-related lung disease. However, there have been no studies
directly measuring functional responses to nucleotides in lung
tissue from human smokers. In the present study we have directly
addressed this issue, and have compared the release of cytokines
from post-mortem human lung tissue from healthy smokers and
non-smokers. We used ATP itself, its stable analogues adenosine 5-
0-3-thiotriphosphate (ATP-c-S) and adenosine 59-a,b-methylene-
triphosphonate (a,b-methylene-ATP), the related nucleotides
ADP, AMP and UTP, P1, P4-diadenosine tetraphosphate (P1,
P4-diATP), 2-methylthioadenosine 59-triphosphate (2-methylthio-
ATP) and 29(39)-O-(4-benzoylbenzoyl)adenosine-59-triphosphate
(Bz-ATP) to stimulate cytokine release in the presence of
lipopolysaccharide (LPS), and have shown for the first time that
smoking dramatically alters the nucleotide-induced release of
proinflammatory cytokines from human lung.
Materials and Methods
The human biological samples were sourced ethically and their
research use was in accord with the terms of the informed
consents. Human lungs from brain dead donors, which were not
suitable for transplantation, were obtained from the National
Disease Research Interchange (Philadelphia), a not-for-profit tissue
procurement organisation based in the USA, under the US
Uniform Anatomical Gifts Act. Consent for research was obtained
from the next of kin, and information received about the donor
included age, sex, race, height, weight, medical history, consump-
tion of alcohol, cigarettes and drugs, time on a ventilator, and
cause of death. Tissue acquisition and the research proposal were
approved internally within GSK and by NDRI (who do not
specifically require IRB approval to supply tissue). Since the
research we perform was within the terms of the original consent,
separate ethical approval was not required for this use of the tissue.
A 5 cm piece of lung parenchyma was finely chopped with scissors
in a Petri dish. The suspension was then filtered through a 1 mm
square sieve into a sterile Petri dish. The filtered fragments were
transferred into a fresh, pre-weighed Falcon tube. Residual tissue
was further chopped using scissors, and filtered once more. These
fragments were added to the pre-weighed Falcon tube and made
up to 50 ml with lung-tissue culture medium (RPMI without
phenol red (GIBCO), containing 0.1% BSA, 100 U/ml penicillin,
2 mM glutamine, 100 mg/ml streptomycin). Fragments were
centrifuged at 200 g for 2 minutes, 5 times to remove blood,
followed by a final spin of 300 g for 5 minutes. The supernatant
was discarded and the pellet weighed. Fragments were plated at
0.04 g/well in 700 ml lung tissue culture medium in a 48 well
tissue culture plate, with care taken to ensure all wells had
approximately the same amount of tissue. Nucleotides (1.4 ml, 4 to
1000 mm final concentration) and/or LPS (7 ml, 10 mg/ml final
concentration) were then added and plates incubated for 24 hours
at 37uC in a 5% CO2 atmosphere. After 24 hours, 200 ml
supernatant was removed from wells, and stored at 280uC.
Cytokine levels in supernatants were analysed using MSD
cytokine multiplex immunoassays (Mesoscale), according to
manufacturer’s instructions. The cytokines measured were IL-1b,
TNFa, IFNc, IL-17, IL-6, IL-8, IL-2 and IL-10. In brief, samples
were defrosted to room temperature and 25 ml was added to the
appropriate well of the MSD plate, and incubated at room
temperature with vigorous shaking for 2 hours. 25 ml of the
appropriate detection antibody was added to each well, and plates
incubated for 1 hour at room temperature with vigorous shaking.
Plates were washed using an automatic plate washer, and 150 ml
per well of 2x MSD Read Buffer diluted in distilled water was
added to the plates. Plates were read within 30 minutes of the
addition of Read Buffer on the MSD SECTOR instrument.
Materials
ATP disodium salt, ATPcS tetralithium salt, a,b-methylene-
ATP lithium salt, ADP disodium salt, AMP disodium salt, UTP
trisodium salt, 2-methylthio ATP tetrasodium salt, P1, P4-diATP
ammonium salt and BzATP triethylammonium salt (Sigma
Aldrich) were made up as 500 mM stock concentrations stored
at 24uC, then diluted further using distilled water. LPS (Sigma
Aldrich) was prepared as a stock concentration of 1 mg/ml with
sterile PBS and stored at 24uC.
Statistical Analysis
The raw data from all studies were analysed for statistical
significance using Graphpad Prism software (Graphpad Software
Inc.). In order to compare the effect of LPS against the untreated
control, a paired two-tailed t-test was used, and to compare the
basal or the LPS-stimulated cytokine levels in smokers and non-
smokers unpaired t tests were used. A one way repeated measures
ANOVA with post-hoc Dunnett’s test was used to compare the
effect of nucleotide in the presence of LPS with LPS alone. These
results were shown as a percentage of the effect of LPS alone in the
graphs in order to reduce the variation between donors. Although
the responses to each nucleotide was analysed separately, multiple
nucleotides have been shown on the same graph for ease of
comparison. For comparison of the effects of ATPcS in smokers
and non-smokers, two-factor ANOVA was used (for the factors
concentration and smoking), with Bonferonni post-hoc tests.
Results
In each of the lungs LPS (10 mg/ml) caused increases in the
release of IL-1b, TNFa, IFNc, IL-17, IL-6, IL-8, IL-2 and IL-10
but the magnitude of the responses varied greatly between donors
and the effects did not achieve statistical significance for IFNc, IL-
8 or IL-2 (Figure 1A, paired t test). When the donors were
separated into smokers and non-smokers, the response to LPS in
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the non-smokers only achieved statistical significance for IL-1b
and IL-17 (Fig. 1C; p,0.05, paired t test). In lungs from the
smokers LPS (10 mg/ml) did not cause a statistically significant
increase in release of any of the cytokines (Fig. 1B; p.0.05, paired
t test). Although the basal cytokine levels in the smokers were
generally higher in the smokers than the non-smokers, there were
no significant differences in either the basal release or the LPS-
stimulated release of any of the cytokines when lungs from smokers
and non-smokers were compared (p.0.05, unpaired t-test).
When a range of nucleotides were tested for their ability to
affect the LPS-stimulated response, ATPcS stimulated the release
of IL-1b and IL-17, an effect which achieved statistical significance
at a concentration of 330 and 1000 mM (p,0.05, one-way
ANOVA), and there was an apparent concentration-dependent
increase in the release of IFNc in response to ATPcS and UTP
which did not achieve statistical significance and where the
individual variation was very large (Figure 2). There was no
significant effect of any other nucleotide (ATP, ADP, AMP, UTP,
a,b-methylene-ATP, P1, P4-diATP, 2-methylthio-ATP, Bz-ATP)
on any other cytokine measured (TNFa, IL-6, IL-8, IL-2 and IL-
10; results not shown).
When the lungs from smokers and non-smokers were compared,
ATPcS significantly enhanced the effect of LPS on the release of
IL-1b in both types of lung at 330 and 1000 mM (one-way
ANOVA), but the effect was significantly greater in the smokers
(Figure 3A; two factor ANOVA). Similarly, for IFNc the effect of
ATPcS was much greater in the smokers and achieved statistical
significance at 330 and 1000 mM (one-way ANOVA), while there
was no effect at all in the non-smokers (Figure 3B). There was no
significant effect of UTP on release of IFNc in either type of lung
(results not shown). For IL-17 the situation was the opposite, with
ATPcS causing a concentration-dependent enhancement of the
effect of LPS in the non-smokers which achieved significance at
330 and 1000 mM (one-way ANOVA), while there was no effect in
the smokers, and there was a significant difference in the responses
of the two types of lung (two factor ANOVA, Figure 3C).
Discussion
The results presented here clearly show that smoking greatly
increases the release of IL-1b and IFNc from human lungs in
response to the non-hydrolysable ATP analogue, ATPcS, while
reducing the release of IL-17. The basal levels of cytokine release
were not significantly affected by smoking, and neither was the
release in the presence of LPS, suggesting that smoking selectively
affects the responses to nucleotides rather than acting to alter
cytokine release non-specifically.
The tissues used in this study were small fragments of post-
mortem human lungs which had been washed free of blood cells
but which still contained a number of different cell types, including
epithelial cells, connective tissue and resident immune cells
including monocytes, macrophages, dendritic cells, lymphocytes
including natural killer (NK) cells and granulocytes [17]. There is
some evidence to suggest that many of these cells occur in larger
numbers in the lungs of smokers but that their function may be
compromised or altered [18]. In pilot studies nucleotides alone
had no effect on cytokine release, so LPS was used to prime the
lung fragments. LPS, a bacterial endotoxin, is known to act via the
Toll-like receptor TLR4, which recognises pathogen-associated
molecular patterns and triggers a widespread immune response
including the release of pro-inflammatory cytokines [19,20]. As
expected, LPS alone increased the release of proinflammatory
cytokines including IL-1b from the lung fragments, and we tested
the effects of nucleotides in the presence of LPS. We used a range
of nucleotides in an attempt to activate the major receptors likely
to mediate the responses and to give some clues as the receptor
type(s) involved. ATP was used as the endogenous agonist at all the
P2X receptors as well as at the P2Y1, P2Y2, P2Y11 receptors, while
Figure 1. Effect of LPS on release of cytokines from human
lung fragments. Post-mortem human lung parenchyma was chopped
and sieved to obtain pieces smaller than 1 mm and incubated for 24 h
at 37uC in the presence (black bars) or absence (white bars) of LPS
(10 mg/ml). The supernatants were then analysed for the cytokines
shown by MSD multiplex immunoassays. A shows the results from all
the lungs (n = 7–12), while B and C show results from smokers (n = 4–7)
and non-smokers (n-3–5) respectively. Values are mean 6 s.e.mean, *
indicates a significant difference between control and LPS-stimulated
values, p,0.05, paired t test.
doi:10.1371/journal.pone.0099711.g001
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UTP was used as the endogenous agonist at P2Y2 and P2Y4, and
ADP as the endogenous agonist at P2Y1, P2Y12 and P2Y13 [21–
23]. ATPcS was used as an analogue of ATP which is resistant to
enzymatic degradation but retains activity at all the receptors on
which ATP is active [23]. a,b-methylene ATP was used as another
stable analogue of ATP which has some selectivity for P2X1 and
Figure 2. Effect of nucleotides on release of cytokines from
human lung fragments in the presence of LPS. Post-mortem
human lung parenchyma was chopped and sieved to obtain pieces
smaller than 1 mm and incubated for 24 h at 37uC in the presence of
LPS (10 mg/ml) alone or in the presence of a range of nucleotides
(ATPcS, ATP, ADP, AMP, UTP, a,b-methylene-ATP, P1, P4-diadenosine
tetraphosphate, 2-methylthio-ATP, Bz-ATP, 4–1000 mM). The superna-
tants were then analysed for cytokines by MSD multiplex immunoas-
says. A, B and C show the results for IL-1b, IFNc and IL-17, n = 3–18,
displayed as % of the release caused by LPS alone, mean 6 s.e.mean. *
indicates a significant difference between the release in the presence of
the nucleotide and that to LPS alone (one-way repeated measures
ANOVA with Dunnett’s post-hoc test) carried out on the data in pg/ml.
doi:10.1371/journal.pone.0099711.g002
Figure 3. Effect of ATPcS on release of cytokines from human
lung fragments from smokers and non-smokers in the
presence of LPS. Post-mortem human lung parenchyma was
chopped and sieved to obtain pieces smaller than 1 mm and incubated
for 24 h at 37uC in the presence of LPS (10 mg/ml) alone or in the
presence of ATPcS (4–1000 mM). The supernatants were then analysed
for cytokines by MSD multiplex immunoassays. A, B and C show the
Smoking Enhances Human Lung Responses to Nucleotides
PLOS ONE | www.plosone.org 4 June 2014 | Volume 9 | Issue 6 | e99711
P2X 3 receptors but has also been shown to as an agonist at P2Y11
receptors [24], P1, P2-DiATP is active at P2Y2 and P2X1
receptors, 2-methylthio-ATP has some selectivity for P2Y1,
P2Y12 and P2X1 receptors while BzATP is more potent than
ATP at the P2X7 receptor [21,23]. Rather than using adenosine
(which is rather insoluble in water) to activate any adenosine
receptors, we used AMP which is inactive at P2 receptors but
rapidly breaks down to adenosine [23].
Of the compounds tested only ATPcS had any significant effect
on cytokine release, and it enhanced the release of IL-1b, IFNc
and IL-17 but not of the other cytokines measured. ATP is rapidly
degraded by dephosphorylation, ultimately to adenosine which
can be taken up or further metabolised by ectonucleotidases which
are present on the surface of all cells and known to play important
roles in immune function [25,26]. Analogues of ATP which have
modifications to the phosphate chain, such as ATPcS and a,b-
methylene ATP, are degraded much more slowly or not at all by
these enzymes while analogues with an unmodified phosphate
chain, such as 2-methylthio-ATP, are rapidly broken down
[27,28]. In the experiments reported here the nucleotides were
incubated with the lung fragments for 24 hours at 37uC, to allow
time for the synthesis and release of the cytokines, so the lack of
effect of most of the nucleotides tested may be due to their
breakdown. Indeed, degradation is well known to reduce greatly
the potency of susceptible analogues in many tissues, and to distort
observed structure-activity relationships [28–30]. The lack of effect
of a,b-methylene ATP however cannot be explained by degrada-
tion of this compound, but instead indicates that P2X1, P2X3
receptors and P2Y11 receptors are unlikely to be involved in the
modulation of cytokine release [21,23,24]. Apart from the P2X7
receptor, P2X receptors are not thought to regulate cytokine
production, but P2Y11 receptors on dendritic cells in particular
have been reported to have complex effects on cytokine
production [31]. The lack of effect of AMP suggests that adenosine
receptors are not important here in modulating cytokine release
although it has been shown to have effects on immune cells which
are generally inhibitory [32].
P2X7 receptors are known to play a key role in the release of IL-
1b from immune cells including macrophages [5–7], and it is likely
that this is the receptor responsible here for the increased IL-1b
release seen with ATPcS in both smokers and non-smokers,
although this can only be a preliminary conclusion in the absence
of data on the effect of a selective P2X7 antagonist on this
response. The large increase in release seen here in the lungs from
smokers is consistent with increased ATP-induced IL-1b release
from immune cells taken from smokers [15], and studies in mice
suggesting a role of ATP and the P2X7 receptor in smoke-induced
pro-inflammatory lung responses [11,12,14]. These studies
reported that smoking caused an upregulation of P2 receptors,
and this may explain the greatly enhanced responses that we
observed. Smoke inhalation has been reported to alter the activity
of ectonucleotidases on blood platelets in rats [33], and nicotine
itself inhibited ectonucleotidase activity in rat lymphocytes [34].
However, changes in ectonucleotidase activity in the lungs of
smokers could not account for the differences that we observed in
the responses to the stable analogue ATPcS between smokers and
non-smokers.
IFNc is a pro-inflammatory cytokine which is the characteristic
product of Th1 lymphocytes [35,36] but is also released by CD8+
(cytotoxic) T cells and a number of innate immune cells such as
NK cells and professional antigen presenting cells [37,38]. Under
the conditions of our experiments it is more likely that this cytokine
was released as part of an innate rather than an adaptive immune
response. Among the numerous functions of IFNc in the immune
system is the activation of macrophages and priming of their
response to LPS [see for example 38,39,40]. Increased production
of IL-1b in response to LPS combined with IFNc has also been
reported from neutrophils [41]. In the present study, ATPcS
increased the release of IFNc from the smokers’ tissue but not
from that of non-smokers, a similar effect to that seen on IL-1b
release. It is not clear from our experiments whether these effects
of ATPcS are related or independent. Caspase-1, which is
activated by P2X7 receptor stimulation, is involved in the release
of both IL-1b and IFNc [42,43] so it is possible that the release of
these two cytokines is coupled. However, given the reported
synergistic effects of LPS and IFNc, it is tempting to speculate that
the increased release of IFNc drives the greater production of IL-
1b particularly as there was a rather smaller, but still statistically
significant, increase in IL-1b secretion in response to ATPcS in the
non-smoker lung tissue in which IFNc production was not
increased. In contrast to the results presented here, ATP (or
ATPcS) has been reported to inhibit IFNc production from a
number of its source innate immune cells by an action on P2Y11
receptors [43]. This may indicate that the effect of smoking is to
modify the response of the IFNc secreting cells to purine
nucleotides, by upregulating P2X7 receptors but not P2Y11
receptors, shifting the response to a more pro-inflammatory
phenotype. It should be noted here that rodents do not appear to
possess a P2Y11 receptor gene [22], so studies on smoke inhalation
in mice [eg 11,12,14] may not necessarily translate to humans.
IL-17 is a pro-inflammatory cytokine, produced by TH17
lymphocytes, which has been implicated in the pathogenesis of
lung disease, including smoking-related emphysema [44–46].
Unlike IL-1b and IFNc the release of IL-17 was enhanced by
ATPcS in the non-smokers but not in the smokers, which may
reflect the complex effects of nucleotides on cytokine release,
which can vary depending on the concentration of agonist (eg
LPS) used to stimulate release, as well as the concentration and
type of cytokine involved [31].
Overall the results presented here clearly demonstrate for the
first time that in normal human lung a stable ATP analogue can
enhance LPS-induced pro-inflammatory cytokine release, and that
these effects are greatly altered by a prior history of smoking.
Further work is needed to determine the receptor type(s) involved
in this response and the target cells, but the findings provide
supportive evidence for a role of purinergic mechanisms in
smoking-induced lung injury.
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